Intramedullary spinal cord abscess treated with antibiotic therapy--case report and review.
A 58-year-old man presented with an intramedullary spinal cord abscess (ISCA) manifesting as posterior neck pain, gait disturbance, and urinary retention, and transverse myelopathy 1 week later. Magnetic resonance imaging showed the ISCA at the C7 to T1 levels. He was treated under a diagnosis of cryptogenic ISCA with high-dose ampicillin and third- or fourth-generation cephalosporins, which resulted in complete recovery after 2 months. Review of the literature between January 1998 and August 2007 identified 26 cases of ISCA, including our patient. We also identified two additional nonsurgically treated ISCA patients reported between 1977 and 2007. The most common presentation was motor deficits in all patients, followed by fever, pain, and bladder dysfunction. The mortality rate was 1 of 26 patients, and neurological sequelae were observed in 15 of the 25 surviving patients. There was no significant difference in the frequency of neurological sequelae between surgically and nonsurgically treated patients. Mean length of the abscess in the surgically treated group was significantly larger than that in the medically treated group (5.8 vs. 2.2 vertebral bodies). All three nonsurgically treated patients with neurological sequelae had anaerobic infections and received antibiotic therapy later and for shorter periods than those with complete neurological recovery. Antibiotic treatment is comparable to surgery plus antibiotic treatment. Early broad-spectrum high-dose ampicillin and third-generation cephalosporin, covering Gram-positive, Gram-negative, and anaerobic organisms, should be the first choice of management for patients with ISCA.
Kurita
Noriaki
N
Department of Medicine, Mitsui Memorial Hospital, Tokyo, Japan.
Sakurai
Yasuhisa
Y
Taniguchi
Makoto
M
Terao
Toru
T
Takahashi
Hiroshi
H
Mannen
Toru
T
D000038:Abscess / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D000667:Ampicillin / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002511:Cephalosporins / Q000008:administration & dosage; D002574:Cervical Vertebrae; D004487:Edema / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology; D020233:Gait Disorders, Neurologic / Q000209:etiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009187:Myelitis / Q000188:drug therapy* / Q000382:microbiology* / Q000473:pathology; D019547:Neck Pain / Q000209:etiology; D012852:Sinusitis / Q000150:complications / Q000382:microbiology; D013116:Spinal Cord / Q000382:microbiology* / Q000473:pathology; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000209:etiology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000667:Ampicillin